echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > NMPA grants Sumitomo Pharmaceuticals atypical antipsychotic drug Rosuda ® imported drug license for the treatment of schizophrenic patients

    NMPA grants Sumitomo Pharmaceuticals atypical antipsychotic drug Rosuda ® imported drug license for the treatment of schizophrenic patients

    • Last Update: 2020-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, s http://
    umitomo Dainippon, a Japanese drug maker, announced that TheRegulatory Authority (NMPA), China's nationaldrug(http:// has granted a license on January 24, 2019 to the atypical antipsychotic drug Latuda ® (general name: luridone Habout Rosuda ®
    Rosuda ® is an atypical antipsychoticdrug(http://with the active ingredient of lurasidone (lulase), discovered and developed by Sumitomo Pharmaceuticals of JapanCompared to other existing anti-schizophrenic drugs, luracedone has a unique chemical structure and is believed to have affinity for dopamine D2, 5-hydroxyseromine (5-HT2A), 5-serotonin (5-HT7) receptors, which have antagonistic effectsIn addition, luracedone has a partial excitable effect on 5-hydroxyamine (5-HT1A) receptors and has no obvious affinity for histamine H1 or toxic alkaloid M1 receptorsin the United States, Rosuda ® was approved in 2010 and 2013 by theFDA(http://for the treatment of schizophrenia and bipolar I depression, and in 2012-2017, Rosuda ® received approval for these two indications in several countries around the world, including two indications, including the Schizophrenia was approved in Taiwan in 2016 and China in China in 2017, and in 2017 it was approved by Taiwan, China, and in the first half of fiscal 2019, Sumitomo Pharmaceuticals plans to submit a application for a new drug (http:// for the treatment of schizophrenia and bipolar I depression in Japan ® sumitomo China Company (http:// Sumitomo Pharmaceuticals (Suzhou) Co., Ltd of Sumitomo Pharmaceuticals, Sumitomo Pharmaceuticals China, submitted an application for an import license for the Rosuda ® to NMPA, China, in December 2015 After completing the necessary formalities, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd is expected to start selling rosuda ® in China in 2019, and the release of the drug will provide a new treatment option for schizophrenics in China
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.